Price Analysis
Table 4 provides a summary of the impact of a price reduction on the likely cost savings associated with rivaroxaban at 12 and 26 months, based on the manufacturer’s assumptions concerning cost of care and monitoring. A price reduction of about 20% would be required to realize cost savings for 12 months of therapy and a price reduction of about 50% would be required to realize savings during 36-month treatment duration.
Table 4
CADTH Common Drug Review Analysis for Price Reduction Scenarios for Rivaroxaban (12 to 36 Months of Treatment Duration).
Additional Reanalyses
CDR also performed a reanalysis on monitoring-cost scenarios to determine the threshold at which rivaroxaban is no longer cost saving at three or six months. Two specific scenarios were looked at: one in which the frequency of monitoring during the first three months was reduced (base case assumed eight visits with attendant testing; Table 5) and a second scenario in which a larger proportion of patients were monitoring through an anticoagulation clinic (where the cost per consultation and attendant testing was estimated to be lower than GP-based monitoring; Table 6).
Table 5
CADTH Common Drug Review Analysis for Monitoring Cost Scenarios for VKA (Consultations and PT Testing) During the First Three Months (Three and Six Months of Total Treatment Duration).
Table 6
CADTH Common Drug Review Analysis for Anticoagulation Clinic Versus GP Clinic Distribution Scenarios for VKA Monitoring (Three and Six months of Total Treatment Duration).
When the number of consultations and PT testing for VKA is reduced, cost savings are still realized for three-month treatment with rivaroxaban. For six months of treatment, during which patients require only five consultations and PT tests, no further cost savings are observed for rivaroxaban.
Using data from a Canadian costing study,2 the manufacturer estimated the cost per consultation and PT test to be $15.95 for an anticoagulation clinic (5% of patients) and $46.52 for GP or community setting (95% of patients); the percentage of patients for each clinic was estimated by the manufacturer based on published literature.1 When varying the proportion of patients tested in the two settings, rivaroxaban remains cost saving when used for three months; however, when 50% of patients are tested in clinic and 50% by GPs, no further cost savings are observed for rivaroxaban.
Publication Details
Copyright
You are permitted to make copies of this document for non-commercial purposes, provided it is not modified when reproduced and appropriate credit is given to CADTH. You may not otherwise copy, modify, translate, post on a website, store electronically, republish, or redistribute any material from this document in any form or by any means without the prior written permission of CADTH.
Please contact CADTH’s Vice-President of Corporate Services at ac.htdac@secivresetaroproc with any inquiries about this notice or other legal matters relating to CADTH’s services.
Except where otherwise noted, this work is distributed under the terms of a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International licence (CC BY-NC-ND), a copy of which is available at http://creativecommons.org/licenses/by-nc-nd/4.0/
Publisher
Canadian Agency for Drugs and Technologies in Health, Ottawa (ON)
NLM Citation
Rivaroxaban (Xarelto): Treatment of Venous Thromboembolic Events (Deep Vein Thrombosis [DVT], Pulmonary Embolism [PE]) and Prevention of Recurrent DVT and PE [Internet]. Ottawa (ON): Canadian Agency for Drugs and Technologies in Health; 2015 Aug. APPENDIX 1, CADTH COMMON DRUG REVIEW ANALYSES.